• Home
  • Search results for: 'research-area pi3k-akt-signaling mtor-signaling'

Search results for: 'research-area pi3k-akt-signaling mtor-signaling'

Shop By
Clear All

Items 1-10 of 12

Page
per page
  1. A-674563
    A8616 A-674563
    Target: Cyclin-Dependent Kinases|Akt|GSK-3|ERK|PKC|PKA|RSK
    Summary: Akt1/PKA/CDK2 inhibitor,potent and selective
      ≥4.9 mg/mL
  2. GSK690693
    A5072 GSK690693
    Target: Akt|PKC|PKG|PKA|Prk
    Summary: Pan-AKT inhibitor,ATP-competitive and potent
      ≥21.25 mg/mL
      insoluble in etoh
      insoluble in h2o
  3. K-252c
    A8344 K-252c
    Target: PKC|PKA
    Summary: Protein kinase inhibitor
      ≥15.55 mg/mL
  4. GF 109203X
    A8342 GF 109203X
     1 Citation
    Target: PKC
    Summary: Protein kinase C,MLCK,PKG and PKA inhibitor
      ≥20.6 mg/mL
  5. Go 6976
    A8341 Go 6976
    Target: PKC
    Summary: PKCα/PKCβ1 inhibitor
      soluble in dmso
  6. RAF265
    A8313 RAF265
    Target: Raf|VEGFR
    Summary: Multiple intracellular kinases inhibitor
      ≥25.9 mg/mL
      ≥7.97 mg/mL
      insoluble in h2o
  7. Enzastaurin (LY317615)
    A1670 Enzastaurin (LY317615)
     2 Citation
    Target: PKC
    Summary: PKC beta inhibitor,potent and selective
      ≥8.6 mg/mL
      insoluble in etoh
      insoluble in h2o
  8. Sorafenib Tosylate
    A8245 Sorafenib Tosylate
     1 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥31.85 mg/mL
      ≥4.15 mg/mL
      insoluble in h2o
  9. Sorafenib
    A3009 Sorafenib
     2 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥23.25 mg/mL
  10. PP121
    B2172 PP121
    Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|Hck
    Summary: Dual inhibitor of tyrosine and phosphoinositide kinases
      ≥15.95 mg/mL

Items 1-10 of 12

Page
per page
Shop By
Now Shopping by
  1. Target PKC Remove This Item
  2. Target Aurora Kinases Remove This Item
  3. Target VEGFR Remove This Item
Clear All
Shopping Options
Category
Specificity
  1. Selective 7 items
Reversibility
  1. Reversible 1 item
Target
  1. Cyclin-Dependent Kinases 1 item
  2. Histone Deacetylases (HDACs) 1 item
  3. Akt 13 items
  4. PI3K 34 items
  5. Raf 8 items
  6. Aurora Kinases 1 item
  7. mTOR 22 items
  8. Androgen Receptors 1 item
  9. FLT3 1 item
  10. GSK-3 7 items
  11. P-glycoprotein (P-gp) 1 item
  12. PLK 1 item
  13. Eph Receptors 1 item
  14. VEGFR 6 items
  15. PDGFR 2 items
  16. p38 4 items
  17. PKB 1 item
  18. JNK 4 items
  19. Bcr-Abl 1 item
  20. MEK 5 items
  21. PORCN 1 item
  22. FGFR 1 item
  23. Smoothened 1 item
  24. Src 1 item
  25. Trk Receptors 1 item
  26. STAT 6 items
  27. EGFR 2 items
  28. Hedgehog 1 item
  29. BMP and Other Activin Receptors 2 items
  30. JAK 2 items
  31. DNA-PK 8 items
  32. HSP90 1 item
  33. CCR 1 item
  34. TNKS 1 item
  35. Toll-like receptors (TLRs) 1 item
  36. ERK 2 items
  37. PKC 6 items
  38. ALK 1 item
  39. PKG 1 item
  40. PKA 4 items
  41. Fatty-acid-binding proteins (FABPs) 1 item
  42. RSK 1 item
  43. ATM/ATR 2 items
  44. Histamine H1 Receptors 1 item
  45. P110 1 item
  46. Hck 1 item
  47. NO Donors / Precursors 1 item
  48. IL Receptors 1 item
  49. BACE 1 item
  50. p70 rsk 1 item
  51. Smoothened receptor 1 item
  52. Antibiotic 1 item
  53. Prk 1 item
  54. Rho 1 item
  55. TRPC channel 1 item
  56. PKD 1 item
  57. FKBP 1 item
  58. ATM 1 item
Reported Experiments
  1. Animal Experiments 12 items
  2. Cell Experiments 10 items
Related Disease
  1. Breast Cancer 2 items
  2. Cancer 10 items
  3. Colon Cancer 1 item
  4. Colorectal Cancer 2 items
  5. Glioblastoma 2 items
  6. Leukemia 2 items
  7. Liver Cancer 1 item
  8. Lymphoma 1 item
  9. Multiple Myeloma 1 item
  10. Ovarian Cancer 1 item
  11. Prostate Cancer 2 items
  12. Renal Cancer 1 item
  13. Thyroid Cancer 1 item